uniQure Stock Rises 12% in Early Trade
uniQure shares slipped to $29.40 in pre-market trading Thursday after surging 11.7% Wednesday, as investors weighed the outlook for its Huntington’s disease gene therapy, AMT-130. The company plans to seek UK marketing approval in Q3 2026 and will meet with the FDA this quarter about a possible Phase III trial. uniQure ended Q1 with $586.6 million in cash and posted a net loss of $53.5 million.